drugset / Trial / NCT03483948
Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase I, open-label, non-randomized, multicenter study to evaluate the safety, pharmacokinetics and preliminary efficacy of HMPL-523 in combination with Azacitidine in previously untreated elderly patients with AML who are not eligible for standard induction therapy.
Timeline
- Start
- 2018-10-09
- Primary completion
- 2019-09-09
- Completion
- 2019-09-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sovleplenib | Small molecule | 800 mg | Oral |
| Background | Azacitidine | Other / unclassified | — | Subcutaneous |